ACT Brief: Epilepsy Trial Feasibility and Family Realities, CRO Partnerships and Strategic Value, and Cortisol and GLP-1 Response

Sep 16, 10:00 AM
Headliner
Share
Subscribe
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
Share
Subscribe
Next
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
Top episodes
AI in Clinical Trials - A Long, But Promising Road Ahead
by Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
by Applied Clinical Trials
Diversity in Clinical Trials: The Need to Take Action
by Applied Clinical Trials